Trials / Active Not Recruiting
Active Not RecruitingNCT06019507
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
A 60 Month, Single-arm, Proof-of-concept Study to Induce Allogeneic Tolerance in Deceased Donor Liver Transplant Recipients Using Siplizumab, an Anti-CD2 Antibody in Combination With Cyclophosphamide and Splenectomy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- ITB-Med LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TCD601 | Investigational Product |
| BIOLOGICAL | Cyclophosphamide | Conditioning Regimen |
| DRUG | TAC | Immunosuppression Therapy |
| DRUG | MMF | Immunosuppression Therapy |
| DRUG | Corticosteroids | Immunosuppression Therapy |
Timeline
- Start date
- 2022-06-29
- Primary completion
- 2026-06-01
- Completion
- 2029-06-01
- First posted
- 2023-08-31
- Last updated
- 2024-11-27
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT06019507. Inclusion in this directory is not an endorsement.